	US 12,134,637 B2
	MART-1(27-35) epitope-specific T cell receptor
Fei Wang, Shenzhen (CN); Chengchi Chao, Shenzhen (CN); Bo Li, Shenzhen (CN); Yong Hou, Shenzhen (CN); Yuelu Yin, Shenzhen (CN); Shilei Wang, Shenzhen (CN); and Kun Duan, Shenzhen (CN)
Assigned to BGI SHENZHEN, Shenzhen (CN)
Appl. No. 17/259,584
Filed by BGI SHENZHEN, Shenzhen (CN)
PCT Filed Jul. 12, 2018, PCT No. PCT/CN2018/095395 § 371(c)(1), (2) Date Jan. 12, 2021, PCT Pub. No. WO2020/010565, PCT Pub. Date Jan. 16, 2020.
Prior Publication US 2022/0340638 A1, Oct. 27, 2022
Int. Cl. C07K 14/725 (2006.01); C12N 5/0783 (2010.01); C12N 5/10 (2006.01); C12N 15/867 (2006.01)

CPC C07K 14/7051 (2013.01) [C12N 5/0636 (2013.01); C12N 5/10 (2013.01); C12N 15/867 (2013.01); C07K 2317/565 (2013.01)]

19 Claims

1. A MART-1 (27-35) epitope-specific T cell receptor, comprising an α chain and a β chain;

the α chain comprises three complementary determining regions, respective amino acid sequences thereof being the amino acid sequences of positions 61-66, positions 84-89, and positions 124-136 of SEQ ID No. 3; and

the β chain comprises three complementary determining regions, respective amino acid sequences thereof being the amino acid sequences of positions 46-50, positions 68-73, and positions 112-125 of SEQ ID No. 4.